ERBB2 and triple-negative breast carcinoma: Of the 12 studies included, two focused on triple-negative breast cancer, two on invasive ductal carcinoma, one on inflammatory breast cancer, one on HER2-amplified breast cancer, one on axillary node-positive breast cancer, and the remaining five on breast cancer as a whole.